149 related articles for article (PubMed ID: 19806507)
21. PANCREATIC SAFETY IN STUDIES OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ALBIGLUTIDE.
Al-Kawas F; Anderson MA; Enns R; Wilson TH; Johnson S; Mallory JM
Endocr Pract; 2019 Jul; 25(7):698-716. PubMed ID: 30865522
[No Abstract] [Full Text] [Related]
22. Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide.
Brønden A; Knop FK; Christensen MB
Clin Pharmacokinet; 2017 Jul; 56(7):719-731. PubMed ID: 28050889
[TBL] [Abstract][Full Text] [Related]
23. Albiglutide: first global approval.
Poole RM; Nowlan ML
Drugs; 2014 Jun; 74(8):929-38. PubMed ID: 24861909
[TBL] [Abstract][Full Text] [Related]
24. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
25. Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes.
Matthews JE; Reinhardt RR; Carr MC
Postgrad Med; 2016 May; 128(4):391-7. PubMed ID: 27043162
[TBL] [Abstract][Full Text] [Related]
26. Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.
Mabilleau G; Mieczkowska A; Chappard D
J Diabetes; 2014 May; 6(3):260-6. PubMed ID: 24164867
[TBL] [Abstract][Full Text] [Related]
27. A novel GLP-1 analog, BPI3006, with potent DPP IV resistance and good glucoregulatory effect.
Li C; Huan Y; Shen N; Ji L; Sun S; Liu S; Liu Q; Gao L; Tan F; Wang Y; Shen Z
Biochem Biophys Res Commun; 2010 Oct; 400(4):563-8. PubMed ID: 20804731
[TBL] [Abstract][Full Text] [Related]
28. Incretins: a new treatment option for type 2 diabetes?
Geelhoed-Duijvestijn PH
Neth J Med; 2007 Feb; 65(2):60-4. PubMed ID: 17379930
[TBL] [Abstract][Full Text] [Related]
29. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
30. BIM-51077, a dipeptidyl peptidase-IV-resistant glucagon-like peptide-1 analog.
Giannoukakis N
Curr Opin Investig Drugs; 2007 Oct; 8(10):842-8. PubMed ID: 17907061
[TBL] [Abstract][Full Text] [Related]
31. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Bourdel-Marchasson I; Schweizer A; Dejager S
Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.
Fisher M; Petrie MC; Ambery PD; Donaldson J; Ye J; McMurray JJ
Lancet Diabetes Endocrinol; 2015 Sep; 3(9):697-703. PubMed ID: 26276240
[TBL] [Abstract][Full Text] [Related]
33. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
Neumiller JJ
Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
[TBL] [Abstract][Full Text] [Related]
34. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Cuthbertson J; Patterson S; O'Harte FP; Bell PM
Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
[TBL] [Abstract][Full Text] [Related]
35. Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research.
Hocher B; Reichetzeder C; Alter ML
Kidney Blood Press Res; 2012; 36(1):65-84. PubMed ID: 22947920
[TBL] [Abstract][Full Text] [Related]
36. GLP-1 based therapies: differential effects on fasting and postprandial glucose.
Fineman MS; Cirincione BB; Maggs D; Diamant M
Diabetes Obes Metab; 2012 Aug; 14(8):675-88. PubMed ID: 22233527
[TBL] [Abstract][Full Text] [Related]
37. [Incretin modulators, a new perspective in diabetes mellitus treatment].
Lupaşcu FG; Geangalău IM; Pânzariu A; Profire L
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):630-4. PubMed ID: 23077965
[TBL] [Abstract][Full Text] [Related]
38. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
[TBL] [Abstract][Full Text] [Related]
39. Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide.
Young MA; Wald JA; Matthews JE; Yang F; Reinhardt RR
Postgrad Med; 2014 May; 126(3):35-46. PubMed ID: 24918790
[TBL] [Abstract][Full Text] [Related]
40. Liraglutide in oral antidiabetic drug combination therapy.
Garber AJ
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
